Search results for " Systemic [Medical Subject Headings]"

showing 10 items of 79 documents

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

2022

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…

Atezolizumab-bevacizumabClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCarcinoma HepatocellularSystemic therapyHepatologyHepatocellular carcinomaTirosin-kinase inhibitorLiver NeoplasmsGastroenterologyTirosin-kinase inhibitor.Atezolizumab-bevacizumab; Hepatocellular carcinoma; Systemic therapy; Tirosin-kinase inhibitorBevacizumabFeasibility StudieTyrosineHumanDigestive and Liver Disease
researchProduct

Pulmonary functional and radiological correlations of nutritional status and physical activity in systemic sclerosis

2011

Purpose Methods and Materials Results Conclusion References Personal Information

CT-High ResolutionConnective tissue disordersPulmonary Function Radiology Nutritional status Physical Activity Systemic SclerosisSettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory system
researchProduct

Climate Change and Energy Issues in the North

2011

Highly industrialized societies are mostly responsible for the emerging anthropogenic climate change. There are different ways to measure this responsibility (e.g., whether based on causal contribution or strict responsibility, see Muller et al. 2007). However, regardless of the specific method applied to measure the impact, presently, the USA and the EU are the global leaders in green house gas emissions with countries such as China, India and Brazil following closely behind. Globally, GHG emissions are still increasing among the highly industrialized countries, particularly in the USA – a country that never ratified the Kyoto Protocol. However, the EU has managed to curb its emissions, co…

Climate change mitigationPolitical economy of climate changeEnvironmental protectionDevelopment economicsGlobal warmingSustainability and systemic change resistanceEnvironmental impact of the energy industryEnvironmental sciencemedia_common.cataloged_instanceKyoto ProtocolEuropean unionEnergy policymedia_common
researchProduct

Editorial Note The path of complexity science: from theory to managerial practice

2012

The application of complexity science to business has always been a diicult task because it is not easy to demonstrate the relevance of complexity theories to practicing managers. We accepted this challenge with this Special Issue, and I think we are giving a good con- tribution in this sense.

Complexity Science Management Consulting systemic thinkingSettore SECS-P/08 - Economia E Gestione Delle Imprese
researchProduct

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in…

2021

Abstract Background There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clini…

Coronary artery abnormalities; Hypotension; Kawasaki disease; Multisystem inflammatory syndrome associated with coronavirus disease; Myocarditis; Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; COVID-19; Child; Child Preschool; Coronary Artery Disease; Cough; Diarrhea; Dyspnea; Female; Glucocorticoids; Heart Failure; Humans; Hyperferritinemia; Hypotension; Immunoglobulins Intravenous; Immunologic Factors; Infant; Intensive Care Units Pediatric; Interleukin 1 Receptor Antagonist Protein; Italy; Lymphopenia; Male; Mucocutaneous Lymph Node Syndrome; Myocarditis; Platelet Aggregation Inhibitors; SARS-CoV-2; Shock; Systemic Inflammatory Response Syndrome; Tachypnea; Troponin T; VomitingMalelcsh:Diseases of the musculoskeletal systemcoronary artery abnormalities; hypotension; kawasaki disease; multisystem inflammatory syndrome associated with coronavirus disease; myocarditis; pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; age distribution; antirheumatic agents; aspirin; C-reactive protein; COVID-19; child ; preschool; coronary artery disease; cough; diarrhea; yspnea; female; glucocorticoids; heart failure; humans; hyperferritinemia; hypotension; immunoglobulins; intravenous; immunologic factors; infant; intensive care units; pediatric; interleukin 1 receptor antagonist protein; italy; lymphopenia; male; mucocutaneous lymph node syndrome; myocarditis; platelet aggregation inhibitors; SARS-CoV-2; shock; systemic inflammatory response syndrome; tachypnea; troponin T; vomitingMyocarditiCoronary Artery Disease030204 cardiovascular system & hematologySARS-CoV-2 Kawasaki disease Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection Myocarditis Hypotension Multisystem inflammatory syndrome associated with coronavirus disease Coronary artery abnormalitiesCoronary artery diseaseSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineGlucocorticoidImmunologic FactorMultisystem inflammatory syndrome associated with coronavirus diseaseImmunology and AllergyChildCoronary artery abnormalitieFisher's exact testPediatricTachypneabiologylcsh:RJ1-570Antirheumatic AgentImmunoglobulins IntravenousShockPediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infectionSettore MED/38Systemic Inflammatory Response SyndromeIntensive Care UnitsMyocarditisC-Reactive ProteinItalyAntirheumatic AgentsChild PreschoolCohortsymbolsPlatelet aggregation inhibitorFemaleHypotensionIntravenousCoronary artery abnormalitiesHumanResearch ArticleDiarrheamedicine.medical_specialtyMyocarditisVomitingImmunoglobulinsMucocutaneous Lymph Node SyndromeIntensive Care Units Pediatric03 medical and health sciencessymbols.namesakeAge DistributionRheumatologyTroponin TInternal medicineLymphopeniamedicineHumansImmunologic FactorsPreschoolGlucocorticoids030203 arthritis & rheumatologyHeart FailureAspirinKawasaki diseasebusiness.industrySARS-CoV-2Platelet Aggregation InhibitorC-reactive proteinCOVID-19Infantlcsh:Pediatricsmedicine.diseaseSystemic inflammatory response syndromeInterleukin 1 Receptor Antagonist ProteinDyspneaCoughImmunoglobulins IntravenouPediatrics Perinatology and Child Healthbiology.proteinKawasaki diseaseHyperferritinemialcsh:RC925-935businessPlatelet Aggregation InhibitorsPediatric rheumatology online journal
researchProduct

Oral dysphagia. An unique symptom for a wide spectrum of diseases

2009

Dysphagia, defined as a difficulty in swallowing of fluids and/or solid foods, is one of the most frequent symptoms of esophageal, gastrointestinal, ear, nose and throat diseases. As such, it poses a diagnostic challenge and an interdisciplinary clinical problem. Of particular importance in diagnosis is to distinguish between esophageal and oropharyngeal dysphagia. Oropharyn-geal dysphagia is often associated with neuromuscular disorders and is treated with rehabilitative protocols, while esophageal dysphagia may be due to anatomical alterations and esophageal motility difficulties. While the former can be adequately treated with endoscopic or surgical therapy, the latter are currently trea…

Diagnosis Differentialdysphagia oral cavity systemic diseasesSettore MED/28 - Malattie OdontostomatologichePredictive Value of TestsRisk FactorsPractice Guidelines as TopicHumansDeglutition DisordersDeglutition
researchProduct

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct

The Case Law of the ECtHR in 2020 in the Light of the Principle of Systemic Harmonisation

2021

This article provides for an overview of some relevant developments in the case-law of the ECtHR in 2020. Priority will be given to Grand Chamber judgments and decisions and those of the Chambers deemed to be relevant from a substantial and procedural viewpoint. Given that in 2020 the Steering Committee for Human Rights published its report on ‘The Place of the European Convention of Human Rights in the International and European Legal Order’, the case-law will be selected and examined from the viewpoint of the principle of systemic harmonisation. The aim is highlighting positive and negative examples of application of general international law by the ECtHR, of cross-fertilisation between t…

ECHRprinciple of systemic harmonisationcross-fertilisationSettore IUS/13 - Diritto InternazionaleEuropean Convention on Human Right
researchProduct

A machine learning application to predict early lung involvement in scleroderma: A feasibility evaluation

2021

Introduction: Systemic sclerosis (SSc) is a systemic immune-mediated disease, featuring fibrosis of the skin and organs, and has the greatest mortality among rheumatic diseases. The nervous system involvement has recently been demonstrated, although actual lung involvement is considered the leading cause of death in SSc and, therefore, should be diagnosed early. Pulmonary function tests are not sensitive enough to be used for screening purposes, thus they should be flanked by other clinical examinations

Elastic net regularizationSpirometryMedicine (General)High-resolution computed tomographyArtificial intelligenceClinical BiochemistryDiseaseMachine learningcomputer.software_genreArticlePulmonary function testingR5-920Machine learningmedicineCause of deathEsophageal dilatationintegumentary systemmedicine.diagnostic_testbusiness.industryHRCT chestRegressionRandom forestArtificial intelligence; Esophageal dilatation; HRCT chest; Machine learning; Systemic sclerosisSystemic sclerosisArtificial intelligencebusinesscomputer
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct